Muscle wasting is a decline in skeletal muscle mass and function that is associated with aging, obesity, and a spectrum of pathologies including cancer. Cancer-associated wasting not only reduces quality of life, but also directly impacts cancer mortality, chemotherapeutic efficacy, and surgical outcomes. There is an incomplete understanding of the role of tumor-derived factors in muscle wasting and sparse knowledge of how these factors impact in vivo muscle regeneration. Here, we identify several cytokines/chemokines that negatively impact in vitro myogenic differentiation. We show that one of these cytokines, CXCL1, potently antagonizes in vivo muscle regeneration and interferes with in vivo muscle satellite cell homeostasis. Strikingly, CXCL1 triggers a robust and specific neutrophil/M2 macrophage response that likely underlies or exacerbates muscle repair/regeneration defects. Taken together, these data highlight the pleiotropic nature of a novel tumor-derived cytokine and underscore the importance of cytokines in muscle progenitor cell regulation.
Introduction
Skeletal muscle maintenance requires balancing opposing forces of muscle breakdown and muscle growth. In healthy individuals, muscle breakdown occurs continuously as a consequence of acute muscle injury, exercise, and daily activity. This breakdown is counteracted by continuous myofiber repair and regeneration. In the context of muscle wasting, however, disease-associated and/or host-derived factors interfere with both muscle breakdown and growth/regeneration processes, ultimately leading to the loss of muscle mass and function. Muscle wasting is a serious concern when present in cancer patients, where the degree of skeletal muscle atrophy is tightly linked to cancer mortality, morbidity, therapeutic prognoses, and quality of life [50] . Although the molecular basis of cancer-associated muscle wasting is unclear, several key mediators are known. Pro-inflammatory cytokines, including IL-1β, IL-6, TNF-α, and IFN-γ, are produced by host immune cells in response to the tumors and/or by the tumor itself and can directly impact skeletal muscle biology in several ways [3, 16] . One way is by suppression of protein synthesis pathways [15] . This occurs through either reduced amino acid uptake or by direct suppression of mRNA transcription and/or translation. Second, wasting may also occur due to enhanced or accelerated protein breakdown. Indeed, the ubiquitin/ proteasome system is one of the most rigorously studied processes associated with muscle wasting, with regulation of ubiquitin, 26S proteasome subunits, and muscle-specific E3 ligases all implicated as mediators or drivers of muscle protein breakdown [4, 33, 36] . Importantly, while much attention has focused on muscle protein disequilibrium in mature muscle/myofibers, fewer studies have examined how muscle regeneration is impaired in the wasting state [48] .
Skeletal muscle regeneration is linked to a pool of muscle stem cells, termed satellite cells SCs), that activates, expands, and self-renews to repair and maintain tissue mass [12] . Loss or functional suppression of this adult stem cell compartment is implicated in diverse muscle pathologies including age-associated sarcopenia [47] , some muscular dystrophies [6, 44] , and cancer-associated cachexia [26, 35] . Furthermore, SC dysfunction/impaired muscle regeneration is observed in multiple muscle atrophy contexts including burn injury [9, 19] , chronic kidney disease [53] , diabetes [2, 31] , and disuse atrophy [38] . Therapies that boost SC regenerative capacity can improve gross muscle mass decline and rescue functional deficits, suggesting that the SC pool is a viable therapeutic target to limit muscle atrophy. In this study, we identified secreted, tumor-derived cytokines able to suppress myogenesis. In vivo evaluation of CXCL1 -a prominent tumor derived factor not previously implicated in muscle wasting -revealed impaired muscle regeneration and satellite cell fusion, defects that may, in part, be attributable to aberrant CXCL1-mediated immune cell regulation. together, our data underscore the complexity of cancer-associated muscle wasting and highlight the utility of using both cell culture and animal models to identify and evaluate novel muscle wasting factors.
Results

Tumor-derived factors interfere with myoblast homeostasis and differentiation
We used an established C2C12 myoblast differentiation model to screen a panel of lung cancer cell line supernatants for the ability to impair myogenic differentiation. In vitro myotube formation was assessed by exposing differentiating myoblasts to conditioned media from exponentially growing Kras LA1/+ ;p53 R172H/Δg/+ lung adenocarcinoma cells and quantifying myotube maturation after 4 days in differentiation/conditioned media. C2C12 myoblasts cultured in the presence of control media exhibited extensive myogenic differentiation, as evidenced by the formation of Myosin Heavy Chain (MyHC)-positive, multi-nucleated myotubes. In contrast, C2C12 cells cultured using conditioned media (CM) from 307P or 531LN2 lung cancer cells formed fewer MyHC + myotubes (control, 307P, 531LN2 mean values = 2.56, 1.40, 1.15 respectively) that failed to mature into elongated, multinucleated structures ( Fig. 1A and B) . Importantly, we did not observe statistically significant myogenic suppression with all lung adenocarcinoma cell lines tested (344SQ, Fig. 1A and B), indicating that CM from 307P and 531LN2 lung cancer cells contains factors that actively suppress differentiation as opposed to simply depleting essential nutrients from base media. To determine whether this differentiation block was associated with defects in cell cycle progression, we performed flow cytometry based cell cycle/S-phase transit assays using 5-ethynyl-2′-deoxyuridine (EdU). We observed a significant decrease in Sphase (EdU) incorporation in 531LN2-CM C2C12 cultures (∼28% in control compared to ∼20% 531LN2-CM) whereas we observed slight, but insignificant deficits in 307P-CM C2C12 cultures ( Fig. 1C and D) . Cultured primary myoblasts similarly treated with either 531LN2 or 307P CM also exhibited minor reductions in Edu incorporation compared to control cells, whereas we observed statistically significant reductions in myogenin (a marker of late myogenic differentiation) expressing cells, compared to control myoblasts ( Supplementary Fig. S1 ).
To evaluate tumor-induced changes to mitochondria biogenesis in muscle cells, we measured mitochondria abundance using a Mitotracker Green dye in our lung cancer (LC)-CM C2C12 cultures. We labeled mitochondria in C2C12 cells cultured in the presence of LC-CM for 24 hours and found a ∼15-20% decrease in Mitotracker Green mean fluorescence intensity (MFI), indicating a decrease in mitochondria mass in the presence of 307P and 531LN2 conditioned media ( Fig. 1E and F) . Taken together, these data show that secreted factors in LC-CM can potently block myogenic differentiation and that these changes may, in part, result from cell line-(or cancer type-) specific defects in cell cycle progression or alterations in mitochondria biogenesis.
Identification of tumor derived secreted cytokines
We next profiled over 100 cytokines/chemokines in 307P, 531LN2 and 344SQ lung cancer line supernatants using antibody arrays to identify secreted factors linked to suppression of myogenic differentiation. We were able to detect 26 proteins above background in at least one of three lung cancer line supernatants. Of these proteins, IGFBP3, LIX/CXCL6, SerpinE1, Osteopontin, and CXCL1/KC/GRO1 exhibited the highest relative signal intensities in our lung cancer supernatants ( Fig. 2A) patterns consistent with the ability of these supernatants to suppress C2C12 differentiation (ref to Fig. 2B ). Based on these expression patterns, we then tested the hypothesis that individual recombinant cytokines can suppress myogenesis. Of the eight cytokines tested (IGFBP3, IGFBP6, CXCL1, CXCL6, CCL2, CCL17, CCL20, Endostatin), three -IGFBP3, CXCL1, and CCL2 -displayed a statistically significant ability to impair in vitro myogenesis, as evidenced by suppression of multinucleated MyHC + myotube maturation ( Fig. 2C and D) . Reverse phase protein array (RPPA) analyses of CXCL1-treated C2C12 cells revealed down-regulation of several signal transduction pathways linked to myogenic differentiation, including PI3K-AKT [21] , ErbB [18, 24] , and HIF-1/AMPK [20] signaling pathways (Supplemental Fig. S2 ). Importantly, while we did not observe suppressive activity with most cytokines tested, we cannot rule out the possibility that specific doses, lots, local concentrations, or cytokine combinations are required for these cytokines to impact myogenic differentiation. Taken together, these experiments revealed two cytokine clusters positively associated with suppression of myogenesis and provide evidence that several individual cytokines, including CXCL1, can directly impact myogenic differentiation.
Tumor bearing mice exhibit weight loss and elevated CXCL1 levels
Given the ability of tumor-derived cytokines to suppress myogenic differentiation and the importance of muscle regeneration/repair in maintenance of muscle mass, we next asked (1) if we could detect elevated CXCL1, the most differentially and highly expressed cytokine identified in our cytokine arrays, in serum and skeletal muscle of tumorbearing mice, and (2) whether tumor-bearing mice exhibited evidence of weight loss. We used a transplant-based approach, previously established using related isogenic lung cancer cell lines [23] , to initiate xenograft tumors in recipient mice. Prior to necropsy, we subjected mice to whole body dual-energy X-ray absorptiometry (DEXA) to quantify total and lean mass in the whole animal. DEXA analyses of mice bearing subcutaneous lung tumors revealed an overall reduction in total body weight excluding the tumor (mean = 24.3 g) compared to non-tumor control mice (mean = 27.0 g) ( Fig. 3A and D) . This decline in overall weight appeared largely attributable to loss of lean mass (mean = 19.0 g vs. 22.4 g). (Fig. 3A and E). Serum analysis of 531LN2-tumor bearing mice revealed a nearly 10-fold increase in serum CXCL1 levels compared to non-tumor bearing healthy control mice (Fig. 3B) . Furthermore, hindlimb TA CXCL1 levels in tumor bearing mice were ∼20-fold higher than control muscle samples (Fig. 3C ). Interestingly, we observed a striking up-regulation (> 200 fold) of cxcl1 mRNA in C2C12 myoblast or myotube cultures exposed to 531LN2 media (Supplemental Fig. S3 ), suggesting that elevated CXCL1 in the skeletal muscle of tumor bearing mice may be the combined result of both tumor-derived CXCL1 as well as tumor-induced CXCL1 production in skeletal muscle. Upon necropsy, we confirmed the DEXA-determined decline in lean mass with tibialis anterior (TA) and gastrocnemius (GR) wet weight measurements ( Fig. 3F and G). Morphometric evaluation of myofiber size further revealed a statistically significant downward shift in the distribution of myofiber feret diameters (Fig. 3H ). Taken together, our data show that lung tumor xenotransplantation results in overall weight loss, a decline in lean mass, and is associated with elevated CXCL1 levels in serum and skeletal muscle.
CXCL1 modulates skeletal muscle regeneration and in vivo satellite cell homeostasis
Skeletal muscle regeneration requires the activation, expansion, and differentiation of satellite cells, a resident adult muscle stem cell population. Given the antagonistic effect of CXCL1 on in vitro myogenesis, as well as increased CXCL1 abundance in lung tumor bearing mice, we next tested the hypothesis that elevated CXCL1 would limit in vivo muscle regeneration. We injured wildtype TA muscle with 1.2% barium chloride (BaCl 2 ) in either a 0.9% saline vehicle or vehicle containing CXCL1. We chose a dose of CXCL1 (100 ng) consistent with CXCL1 levels detected in cancer-associated muscle (ref to Fig. 3C ). Additional injections of vehicle or vehicle/CXCL1 were given 2 and 4 days following injury to maintain elevated CXCL1 levels (see experimental timeline in Fig. 4A ). Seven days following injury, we sacrificed experimental mice, harvested TA muscles, and performed immunohistochemical analyses. Myofiber feret diameters measured 7d post injury were significantly smaller in vehicle/CXCL1 samples compared to vehicle only controls (control mean = 36um, CXCL1 mean = 19um) ( Fig. 4B and C) . We observed a ∼50% increase in Pax7+ cell numbers (Fig. 4D ) and a nearly 3-fold increase in the number of muscle resident CD45 + immune cells (Fig. 4E) . Interestingly, tumor-bearing mice also exhibited elevated (∼4.5 fold) CD45+ cell numbers in hindlimb muscle preparations analyzed by flow cytometry (Supplemental Fig. S4 ). Together, these data support the hypothesis that CXCL1 impairs muscle regeneration.
We next leveraged a recently described SC lineage tracing vs. ∼28 cells/mm 2 CXCL1) ( Fig. 5B and C) , indicating deficits in SC commitment and/or fusion consistent with published studies [26] . Additionally, the tdTomato + SC/tdTomato + myofiber ratio was elevated ∼2-fold (Fig. 5D ), suggesting that CXCL1 results in SC expansion or accumulation at the expense of cell cycle exit and commitment to differentiation and fusion. Strikingly, we observed evidence of elevated CD45 + immune cell numbers in the absence of overt injury ( [11] . To identify the nature of the infiltrating CD45 + immune cell population, we used flow cytometry-based antibody panels to query the spectrum of immune cell subtypes present in skeletal muscle before and after an acute CXCL1 injection. In total, we assessed the presence of Tcells (cytotoxic, regulatory, and helper), macrophages (M1 and M2), neutrophils, dendritic cells, and natural killer (NK) cells in wildtype mice +/-CXCL1. Consistent with our immunofluorescence analyses, we detected a ∼3 fold increase in CD45+ cells in the CXCL1-injected cohort after an acute dose (24 h) of CXCL1 ( Fig. 6A and B) . Most of this increase was attributable to statistically significant neutrophil and M2 macrophage expansion ( Fig. 6C and D) . Overall, these data therefore show that CXCL1 can elicit a potent neutrophil/macrophage response, and that together with the ability to suppress myogenic differentiation, likely contributes to cancer-associated muscle wasting.
Discussion
We focused on identifying and characterizing tumor-derived factors that interfere with myogenic progression, in part based on accumulating evidence that impaired regeneration/repair contributes to cancer-associated wasting [26, 48] . Consistent with loss of muscle mass, we show that tumor-derived factors interfere with myoblast differentiation and cell cycle progression. Furthermore, we observe decreased mitochondrial biogenesis which is consistent with reported tumor-mediated decrements in respiratory chain activity [40, 17] or dysregulated ATP generation [45, 51] . We then implicate one of these tumor-derived factors -CXCL1 -in muscle repair/regeneration and in vivo SC homeostasis. Taken together, we propose that cytokine-mediated disruption of myoblast function is a potential mechanism to partially explain loss of lean mass observed in 531LN2 lung tumor bearing mice.
To demonstrate the modulatory effects of CXCL1 on in vivo myogenesis, we utilized a murine SC lineage tracing model that tracked tdTomato fluorescence in Pax7 + SCs and all progeny including myofibers). We observed an accumulation of lineage marked cells and an increase in the SC/myofiber ratio in CXCL1 treated mice, implicating satellite cell differentiation defects. Several reports in stem cells [27] , fibroblasts [32] , and cancer cells [7, 32] suggest that CXCL1 can function as a mitogen. Thus, CXCL1 may inhibit differentiation by antagonizing cell cycle exit and promoting SC proliferation. Alternatively, overexpression studies showed that CXCL1 can modulate skeletal muscle metabolism [42] . Given the dynamic metabolic changes occurring during myogenic differentiation [43] , it is possible that elevated CXCL1 levels impair SC metabolism or protein synthesis/accretion to limit muscle regeneration. Future studies more rigorously investigating the cellular and molecular impact of CXCL1 (and other tumor- associated cytokines) on SCs is needed to fully appreciate the mechanism by which myogenesis is impaired. In addition to tumor-derived secretion of CXCL1 [1, 14, 29, 34, 37] , CXCL1 is secreted by several tissues which influence the physiology of skeletal muscle, including liver [42] and immune cells, namely neutrophils [28, 30] . Interestingly, CXCL1 stimulated both neutrophil and M2-type macrophage expansion in skeletal muscle. During muscle regeneration, neutrophils and M2 macrophages are generally thought to drive distinct repair processes, with the former promoting cell clearance while the latter aids tissue repair and remodeling [49] . That CXCL1 promotes rapid expansion of these distinct immune cell subpopulations in skeletal muscle suggests that impaired regeneration may result, in part, from disruption of the ordered recruitment of immune cell subtypes to damaged muscle. Given the well-documented influence of the immune system on satellite cell function and muscle regeneration, our work underscores the importance of evaluating myogenic factors both in vitro and in relevant physiological settings to more fully reveal potential mechanisms of action.
Potentiating myogenesis has proven effective in mitigating functional deficits associated with other skeletal muscle wasting disorders such as age-associated sarcopenia and muscular dystrophy [5, 10, 13] . In some of these contexts, removing disease or age-associated blocks that impaired SC activity were sufficient to attenuate or even reverse muscle atrophy [46, 22] . Importantly, enhancing muscle regeneration would likely complement other therapeutic strategies, such as those that target aberrant immune cell activity and/or hyperactive muscle breakdown pathways. Ultimately, slowing and/or reversing cancer-associated muscle wasting will likely require a therapeutic program that incorporates both pro-regeneration and anti-breakdown strategies.
In summary, we describe a role for CXCL1 in negatively regulating muscle regeneration and satellite cell homeostasis, and altering the immune cell profile in skeletal muscle. That CXCL1 can impair both myogenesis and immune cell homeostasis underscores the likelihood that other cytokines act on multiple cellular targets during muscle regeneration/repair. Thus, as anti-cytokine therapies move forward, it will be important to consider all potential target cells/signaling pathways in order to avoid or minimize off-target effects.
Methods
Animals
Mice were bred and housed according to NIH guidelines for the ethical treatment of animals in a pathogen-free facility at the Mayo Clinic (Rochester, MN campus). Mayo Clinic's Institutional Animal Care and Use Committee (IACUC) approved all animal protocols. The following mouse strains were used in this study: Pax7 iCreERT2 [39] , RO-SA26 LSL-tdTomato Jackson Labs, 007909), and Pax7zsgreen [8] . Wild type mice were C57BL/6J Jackson Labs) or FVB Charles River Labs). Pax7 + SCs were lineage marked as described previously [41] with a tdTomato fluorophore using tamoxifen/cre-mediated recombination. Using this mouse model, recombinant CXCL1 was injected in the right hindlimb TA muscle and a vehicle control injected in the contralateral limb. Cre-mediated recombination was induced via intraperitoneal injections of tamoxifen (Sigma Aldrich) in corn oil dosed at 2 mg tamoxifen/20 g mouse weight. ** p < .01 using two-tailed, unpaired t tests. (H) Histograms depicting binned myofiber feret diameter measurements from control and 531LN2 tumor bearing mice. Non-linear regression curves were fit (least squares method) to each sample and compared using extra sum-of-squares F tests to determine if regression curves were statistically different (p < .0001).
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Cytokine 107 (2018) [9] [10] [11] [12] [13] [14] [15] [16] [17] recipient mice [23] . Mice were monitored twice weekly and imaged at the end of the study (∼6 weeks post injection).
Animal imaging
Imaging-based determination of total mass and lean mass was performed following induction of anesthesia (ketamine/xyzaline). Scanning was performed on a restrained mouse using dual-energy X-ray absorptiometry (DEXA; PIXImus; Lunar Inc.) and analyzed using manufacturer included software.
Cell culture
C2C12 cells (ATCC) [52] were grown on tissue culture treated dishes in growth media consisting of DMEM media supplemented with 10% fetal bovine serum and antibiotics. Differentiation-inducing media replaces 10% FBS with 2% horse serum. Primary dispersed SCs were isolated and cultured as previously described [25] . Conditioned media from lung adenocarcinoma cells was collected by culturing cells (∼70-90% confluence) in serum free (DMEM) media for 8 hours, followed by centrifugation of cell debris and adding serum as needed (10% FBS for growth experiments, 2% horse serum for differentiation experiments). Differentiating cultures were maintained by alternating fresh media additions and complete media changes on a daily basis for up to 5 days. Kras LA1/+ ;p53 R172H/Δg/+ lung adenocarcinoma cell lines 307P, 531LN2, 344SQ) were generated as previously described [23] .
Immunostaining
Tissue sections (8-10 μm) were post-fixed in 4% paraformaldehyde for 5 min at room temperature prior to immunostaining. Once fixed, isolated SCs, myofibers or tissue sections were permeabilized with 0.5% Triton-X100 in PBS followed by blocking with 3% BSA in PBS. Primary antibody incubations occurred at RT for 90 min or overnight at 4 degrees followed by incubation with secondary antibody at RT for 30 min in 3% BSA in PBS. The following antibodies were used in this study: EdU) for 2 h, fixing, counterstaining DNA with DAPI, and identifying Edu + cells using a Click-IT Edu Flow Cytometry Kit Thermo Fisher). Mitochondria were labeled in live cells using MitoTracker Green FM Thermo Fisher) and analyzed by flow cytometry. Immune cell profiling was performed as follows: hindlimb muscles were enzymatically digested and filtered according to standard protocols [5] , cells were labeled with fluorescently conjugated primary antibodies according to manufacturer's instructions, and flow cytometry performed on a MACSquant 10 analyzer. The following antibodies (Miltenyi Biotec) were used in this study: anti-CD45, anti-CD3, anti-CD49b, anti-CD11c, anti-MHC class II, anti-F4/80, anti-CD11c, and anti-GR1. The following is the gating strategy used to identify individual immune cell subtypes: NK: CD45+, CD3e-, CD49b+; Dendritic cell: CD45+, CD11c+, MHC class II+; M1 macrophage: CD45+, F4/80+, CD11b+, CD11c+; M2 macrophage: CD45+, F4/80+, CD11b+, CD11c−; Neutrophil: CD45+, CD11b+, GR1+; Pan T cells: CD45+, CD3e+; Cytotoxic T cells: CD45+, CD3e+, CD8+; Helper T cells: CD45+, CD3e+, CD4+; Regulatory T cells: CD45+, CD3e+, CD4+, CD25+. Samples were analyzed using either MACSquant software or FlowJo v10.
Cytokine studies
Conditioned media from lung adenocarcinoma cells was collected as described above for C2C12 studies. Cytokine arrays were performed using Proteome Profiler Mouse XL Cytokine Arrays (R&D Systems) and visualized/quantified using a LI-COR Odyssey FC system. Ectopic cytokine studies were performed using C2C12 cells plated at a density of 100-500 K/well of a 6-well tissue culture dish and differentiated as noted above for conditioned media experiments. Signaling (RPPA) studies were performed using a starting cell density of 180K/well of a 6-well tissue culture dish. All cytokines were purchased from Peprotech and used as noted in the text based on published IC50 ranges defined in other cell types/experimental contexts: IGFBP3 (cat#: 100-008), IGFBP6 (cat#: 350-07B), CXCL1 (cat#: 250-11), LIX/CXCL6 (cat#: 250-17), CCL2 (cat#: 250-10), CCL17 (cat#: 300-30), CCL20 (cat#: 250-27), and endostatin (cat#: 150-01). We noted substantial lot-to-lot variability with the CXCL1 preparations, so we advise recalibrating phenotypes if using different cytokine lots. CXCL1 ELISAs were performed using a Mouse CXCL1/KC DuoSet ELISA kit (R&D Systems) and serum or liquid nitrogen prepared whole muscle lysates from terminal tumor-bearing (531LN2) mice. 
